Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. (10th March 2021)

• Record Type: Journal Article
• Authors: Lin, Dan-Yu; Zeng, Donglin; Gilbert, Peter B
• Is Part Of: Clinical infectious diseases. Volume 73:Number 10(2021)
• Page Start: 1927
• Page End: 1939
• Publication Date: 2021-03-10
• Subjects: booster vaccination -- crossover -- durability of vaccine efficacy -- phase 3 trials -- SARS-CoV-2 -- waning efficacy; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab226
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Large-scale deployment of safe and durably effective vaccines can curtail the coronavirus disease-2019 (COVID-19) pandemic. However, the high vaccine efficacy (VE) reported by ongoing phase 3 placebo-controlled clinical trials is based on a median follow-up time of only about 2 months, and thus does not pertain to long-term efficacy. To evaluate the duration of protection while allowing trial participants timely access to efficacious vaccine, investigators can sequentially cross participants over from the placebo arm to the vaccine arm. Here, we show how to estimate potentially time-varying placebo-controlled VE in this type of staggered vaccination of participants. In addition, we compare the performance of blinded and unblinded crossover designs in estimating long-term VE. Abstract : We show how to estimate the potentially waning long-term efficacy of COVID-19 vaccines using data from randomized, placebo-controlled clinical trials with staggered enrollment of participants and sequential crossover of placebo recipients.